Trial Profile

An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rotavirus W179-9 vaccine (Primary) ; Measles vaccines; Meningococcal vaccine conjugate; Yellow fever vaccine
Indications Rotavirus infections
Focus Pharmacodynamics

12 Apr 2018 Primary endpoint (The immune response will be parameterized as the yellow fever virus neutralizing antibody seroconversion rate) has not been met as per the results published in the Journal of Infectious Diseases.
12 Apr 2018 Primary endpoint (The immune response will be parameterized as the measles virus neutralizing antibody seroconversion rate) has been met as per the results published in the Journal of Infectious Diseases.
12 Apr 2018 Results published in the Journal of Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com